DNA

Ginkgo Bioworks Holdings, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1830214Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$170.0M

Net Income FY2025

$(313.0M)

EPS (Basic, as reported)

$-5.64

Net Margin FY2025

-183.8%

ROE FY2025

-61.5%

Total Equity

$509.0M

Shares Out

—

Business description

Ginkgo Bioworks Holdings, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 54 → 170 +21.1% CAGR

Fiscal yearFY2019FY2020FY2021FY2022FY2023⚑FY2024FY2025

Revenue5477314478251227170

Research & development(96)(160)(1,150)(1,053)(581)(424)(244)

General & administrative(29)(38)(863)(1,430)(385)(246)(183)

Total operating expenses(126)(214)(2,142)(2,687)(1,116)(787)(485)

Operating income(72)(137)(1,828)(2,209)(864)(560)(315)

Interest expense(2)(2)(2)0000

Other income (expense), net—12(10)88(29)122

Pre-tax income(120)(125)(1,838)(2,121)(893)(548)(314)

Income tax expense0(2)(1)(15)00(1)

Net income(119)(127)(1,830)(2,105)(893)(547)(313)

EPS — basic($0.10)($0.10)($1.35)($1.25)($0.46)($10.54)($5.64)

EPS — diluted($0.10)($0.10)($1.39)($1.25)($0.46)($10.54)($5.64)

Shares outstanding — basic (M)1,1491,2751,3601,6791,9445255

Shares outstanding — diluted (M)1,1491,2751,3601,6801,9445255

⚑ Weighted-average shares changed ÷33.33 between FY2023 and FY2024 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.